Biosimilars pipeline

The Teva U.S. Biosimilars Pipeline provides an overview of biosimilar products approved, under regulatory review, or in development for the U.S. market. This page focuses specifically on biosimilar programs relevant to the United States and includes products developed in collaboration with partners such as Alvotech, mAbxience and Polpharma. For information about Teva's broader global portfolio of innovative medicines and biosimilars, please refer to the Global R&D Pipeline.

Explore Teva's Global R&D Pipeline to learn more about innovative medicines and biosimilar development worldwide.

Explore Teva's Global R&D Pipeline
  • Approved
  • Under Regulatory Review
  • Clinical
  • Pre-Clinical

Approved

PONLIMSI®

(denosumab-adet)
  • Osteoporosis

DEGEVMA®

(denosumab-adet)
  • Oncology

Under Regulatory Review

Biosimilar candidate to Simponi®

(golimumab)
  • Immunology

In collaboration with Alvotech for the U.S. Market

Biosimilar candidate to Simponi Aria®

(golimumab)
  • Immunology

In collaboration with Alvotech for the U.S. Market

Biosimilar candidate to Eylea®

(aflibercept)
  • Ophthalmology

In collaboration with Alvotech for the U.S. Market

Biosimilar candidate to Xolair®

(omalizumab)
  • Immunology
  • Respiratory

Biosimilar candidate to Entyvio®

(vedolizumab) IV
  • Immunology

In collaboration with Alvotech for the U.S. Market

Biosimilar candidate to Entyvio®

(vedolizumab) SC
  • Immunology

In collaboration with Alvotech for the U.S. Market

Clinical

TEV-'292

  • Ophthalmology

In collaboration with Alvotech for the U.S. Market

TEV-'333

  • Oncology

In collaboration with mAbxience

TEV-'316

  • Oncology

In collaboration with mAbxience

Pre-Clinical

TEV-'295

  • Immunology

In collaboration with Alvotech for the U.S. Market

TEV-'296

  • Immunology

In collaboration with Alvotech for the U.S. Market

Biosimilar candidate to Ocrevus®

(ocrelizumab)
  • Neurology

In collaboration with Polpharma

Biosimilar candidate to Ocrevus Zunovo®

(ocrelizumab and hyaluronidase-ocsq)
  • Neurology

In collaboration with Polpharma

No drugs found for your filtering criteria

Your filtering criteria did not match any drugs we currently have in the pipeline. Reset filters to see all drugs or modify your filtering criteria.

Reset All Filters

Ocrevus® and Ocrevus Zunovo® are registered trademarks of Genentech, Inc. Simponi® and Simponi Aria® are registered trademarks of Johnson & Johnson. Eylea® is a registered trademark of Regeneron Pharmaceuticals, Inc. Xolair® is a registered trademark of Novartis AG. Entyvio® is a registered trademark of Millennium Pharmaceuticals, Inc.

FAQ

What does the U.S. Biosimilars Pipeline include?

Toggle Expand/Collapse

This page provides an overview of Teva's biosimilar candidates that are approved, under regulatory review, or in development for the U.S. market. It focuses specifically on biosimilars and related development activities relevant to the United States.

How is this different from Teva's Global R&D Pipeline?

Toggle Expand/Collapse

The Global R&D Pipeline includes Teva's broader portfolio of innovative medicines and biosimilars across all therapeutic areas and development stages worldwide. The U.S. Biosimilars Pipeline focuses specifically on biosimilar programs relevant to the U.S. market.

NPS-US-NP-02089